Back to top

messenger-rna: Archive

Zacks Equity Research

Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Novavax (NVAX) Receives FDA Nod for COVID-19 Booster Jab

Novavax (NVAX) gets FDA authorization for using its COVID vaccine as a booster dose in adults after six months of completing the primary vaccine regimen.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer (PFE) Posts Positive Data on Bivalent BA.4/5 COVID Jab

Pfizer (PFE) and partner BioNTech's Omicron BA.4/BA.5-adapted bivalent COVID vaccine exhibits substantial antibody response above pre-booster levels in adults after seven days of dose administration.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Sundeep Ganoria

FDA Allows Emergency Use of Omicron-Based COVID Jabs in Kids

Anticipating a surge of COVID-19 infections later this year, the FDA broadens the label of authorized Omicron-based BA.4/BA.5 adapted bivalent boosters to include children as young as five years.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Moderna (MRNA) Up After Merck Exercises Option for Cancer Jab

Merck (MRK) exercises an option to jointly develop and commercialize Moderna's (MRNA) personalized cancer vaccine as part of an existing collaboration agreement between the companies.

MRKPositive Net Change MRNAPositive Net Change CPRXPositive Net Change AERIPositive Net Change

Zacks Equity Research

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222, designed to target the Omicron BA.4 and BA.5 subvariants.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent COVID vaccine for children. It is already authorized for use in adolescents and adults.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Why Novavax (NVAX) Stock Was Down 13% on Thursday

Novavax (NVAX) sinks to a new record level 52-week low after analysts at JP Morgan cut the 12-month target price on the stock by more than $100.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.

PFEPositive Net Change MRNAPositive Net Change BNTXPositive Net Change